Francis Knuettel II - Feb 21, 2024 Form 4 Insider Report for Chromocell Therapeutics Corp (CHRO)

Role
Interim CEO, CFO Treas & Secty
Signature
/s/ Francis Knuettel II
Stock symbol
CHRO
Transactions as of
Feb 21, 2024
Transactions value $
$0
Form type
4
Date filed
2/23/2024, 05:17 PM
Previous filing
Feb 15, 2024
Next filing
Jun 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRO Employee Stock Option Award -2.78K -10% 25K Feb 21, 2024 Common Stock 2.78K $22.68 Camden Capital LLC F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.
F2 On January 10, 2023, Camden Capital LLC was granted stock options to purchase 2,778 shares of common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering.